1614P Long-term outcome of adding the histone deacetylase inhibitor (HDACi) domatinostat (DOM) to neoadjuvant (neoadj) nivolumab (NIVO) +/- ipilimumab (IPI) in interferon-gamma signature (IFNγ) high/low stage III melanoma patients (pts)
Lianne Hoeijmakers, Irene L. M. Reijers, A.M. Menzies, Petros Dimitriadis, Marta López‐Yurda, Sten Cornelissen, Michel W.J.M. Wouters, R. Saw, M. Klop, Thomas E. Pennington, W. Van Houdt, L.J.W. Bosch, L. Grijpink-Ongering, R. Rawson, Andrew J. Spillane, Richard A Scolyer, B. van de Wiel, Alexander C.J. van Akkooi, G.V. Long, C.U. Blank (2025). 1614P Long-term outcome of adding the histone deacetylase inhibitor (HDACi) domatinostat (DOM) to neoadjuvant (neoadj) nivolumab (NIVO) +/- ipilimumab (IPI) in interferon-gamma signature (IFNγ) high/low stage III melanoma patients (pts). , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.2242.
